| Ixabepilone in Treating Young Patients With Refractory Solid Tumors (NCT00331643) | National Cancer Institute (NCI) | 2006-04-01 |
| SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT00337194) | National Cancer Institute (NCI) | 2006-04-01 |
| Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy (NCT00331344) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma (NCT00329719) | National Cancer Institute (NCI) | 2006-03-24 |
| Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer (NCT00304460) | National Cancer Institute (NCI) | 2006-03-13 |
| Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma (NCT00336063) | National Cancer Institute (NCI) | 2006-03-03 |
| Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors (NCT00302159) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer (NCT00324740) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors (NCT00324480) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer (NCT00330161) | National Cancer Institute (NCI) | 2006-03-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors (NCT00331955) | National Cancer Institute (NCI) | 2006-03-01 |
| AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors (NCT00326664) | National Cancer Institute (NCI) | 2006-03-01 |
| Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer (NCT00331682) | National Cancer Institute (NCI) | 2006-03-01 |
| Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia (NCT00335504) | National Cancer Institute (NCI) | 2006-03-01 |
| AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer (NCT00303862) | National Cancer Institute (NCI) | 2006-03-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00253578) | National Cancer Institute (NCI) | 2006-03-01 |
| AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer (NCT00245063) | National Cancer Institute (NCI) | 2006-03-01 |
| Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00301964) | National Cancer Institute (NCI) | 2006-03-01 |
| Actigraph Accelerometer Validation Study (NCT00342212) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes (NCT00331513) | National Cancer Institute (NCI) | 2006-03-01 |
| Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate (NCT00316953) | National Cancer Institute (NCI) | 2006-03-01 |
| Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma (NCT00295984) | National Cancer Institute (NCI) | 2006-03-01 |
| S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas (NCT00217620) | National Cancer Institute (NCI) | 2006-03-01 |
| Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00109824) | National Cancer Institute (NCI) | 2006-03-01 |
| Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies (NCT00335998) | National Cancer Institute (NCI) | 2006-03-01 |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma (NCT00301795) | National Cancer Institute (NCI) | 2006-03-01 |
| Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine (NCT00342693) | National Cancer Institute (NCI) | 2006-02-21 |
| Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (NCT00305864) | National Cancer Institute (NCI) | 2006-02-09 |
| Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China (NCT00482118) | National Cancer Institute (NCI) | 2006-02-06 |
| Natural History Study of Moles and Suspicious Melanoma (NCT00288938) | National Cancer Institute (NCI) | 2006-02-03 |
| BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma (NCT00287495) | National Cancer Institute (NCI) | 2006-02-02 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (NCT00275080) | National Cancer Institute (NCI) | 2006-02-01 |
| Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer (NCT00262821) | National Cancer Institute (NCI) | 2006-02-01 |
| A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer (NCT00108732) | National Cancer Institute (NCI) | 2006-02-01 |
| O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors (NCT00275002) | National Cancer Institute (NCI) | 2006-02-01 |
| Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT00112684) | National Cancer Institute (NCI) | 2006-02-01 |
| Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00324870) | National Cancer Institute (NCI) | 2006-02-01 |
| Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery (NCT00305877) | National Cancer Institute (NCI) | 2006-02-01 |
| Pilots of Self-Collection for HPV DNA Detection (NCT00342511) | National Cancer Institute (NCI) | 2006-01-09 |
| Vorinostat in Treating Patients With Acute Myeloid Leukemia (NCT00305773) | National Cancer Institute (NCI) | 2006-01-01 |
| Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (NCT00182767) | National Cancer Institute (NCI) | 2006-01-01 |
| Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer (NCT00079040) | National Cancer Institute (NCI) | 2006-01-01 |
| AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme (NCT00305656) | National Cancer Institute (NCI) | 2006-01-01 |
| Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men (NCT00287833) | National Cancer Institute (NCI) | 2006-01-01 |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia (NCT00278330) | National Cancer Institute (NCI) | 2006-01-01 |
| Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer (NCT00321893) | National Cancer Institute (NCI) | 2006-01-01 |
| Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma (NCT00273910) | National Cancer Institute (NCI) | 2006-01-01 |
| Oxaliplatin and Topotecan in Advance Ovarian Cancer (NCT00313612) | National Cancer Institute (NCI) | 2006-01-01 |
| Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer (NCT00290758) | National Cancer Institute (NCI) | 2006-01-01 |
| PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT00303953) | National Cancer Institute (NCI) | 2006-01-01 |
| AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer (NCT00310089) | National Cancer Institute (NCI) | 2006-01-01 |
| Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer (NCT00126659) | National Cancer Institute (NCI) | 2006-01-01 |
| AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (NCT00243061) | National Cancer Institute (NCI) | 2006-01-01 |
| ZD6474 to Treat Advanced Brain Cancer in Patients (NCT00272350) | National Cancer Institute (NCI) | 2005-12-29 |
| Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (NCT00268385) | National Cancer Institute (NCI) | 2005-12-16 |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers (NCT00086567) | National Cancer Institute (NCI) | 2005-12-12 |
| Sorafenib and Bortezomib in Treating Patients With Advanced Cancer (NCT00303797) | National Cancer Institute (NCI) | 2005-12-01 |
| Bevacizumab for Recurrent Malignant Glioma (NCT00271609) | National Cancer Institute (NCI) | 2005-12-01 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer (NCT00134043) | National Cancer Institute (NCI) | 2005-12-01 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia (NCT00301769) | National Cancer Institute (NCI) | 2005-12-01 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00255762) | National Cancer Institute (NCI) | 2005-12-01 |
| 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (NCT00301938) | National Cancer Institute (NCI) | 2005-12-01 |
| Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function (NCT00275093) | National Cancer Institute (NCI) | 2005-12-01 |
| Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00290810) | National Cancer Institute (NCI) | 2005-12-01 |
| Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery (NCT00309946) | National Cancer Institute (NCI) | 2005-12-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery (NCT00227760) | National Cancer Institute (NCI) | 2005-12-01 |
| Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (NCT00227591) | National Cancer Institute (NCI) | 2005-12-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (NCT00112723) | National Cancer Institute (NCI) | 2005-12-01 |
| Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT00238394) | National Cancer Institute (NCI) | 2005-12-01 |
| Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining (NCT00242723) | National Cancer Institute (NCI) | 2005-11-09 |
| S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery (NCT00243074) | National Cancer Institute (NCI) | 2005-11-01 |
| Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer (NCT00245024) | National Cancer Institute (NCI) | 2005-11-01 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma (NCT00303836) | National Cancer Institute (NCI) | 2005-11-01 |
| Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00243100) | National Cancer Institute (NCI) | 2005-11-01 |
| Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia (NCT00303966) | National Cancer Institute (NCI) | 2005-11-01 |
| Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus (NCT00233935) | National Cancer Institute (NCI) | 2005-11-01 |
| Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00310024) | National Cancer Institute (NCI) | 2005-11-01 |
| Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain (NCT00301847) | National Cancer Institute (NCI) | 2005-11-01 |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer (NCT00253370) | National Cancer Institute (NCI) | 2005-10-01 |
| Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung (NCT00301730) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (NCT00217646) | National Cancer Institute (NCI) | 2005-10-01 |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer (NCT00107536) | National Cancer Institute (NCI) | 2005-10-01 |
| Vorinostat in Treating Patients With Kidney Cancer (NCT00278395) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (NCT00278382) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium (NCT00112905) | National Cancer Institute (NCI) | 2005-10-01 |
| S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma (NCT00238212) | National Cancer Institute (NCI) | 2005-10-01 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma (NCT00288041) | National Cancer Institute (NCI) | 2005-10-01 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT00288067) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma (NCT00131937) | National Cancer Institute (NCI) | 2005-10-01 |
| Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer (NCT00262834) | National Cancer Institute (NCI) | 2005-10-01 |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00275028) | National Cancer Institute (NCI) | 2005-10-01 |
| Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (NCT00244972) | National Cancer Institute (NCI) | 2005-10-01 |
| Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer (NCT00119262) | National Cancer Institute (NCI) | 2005-10-01 |
| Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer (NCT00132067) | National Cancer Institute (NCI) | 2005-10-01 |
| Genetic Predictors of Cardiovascular Disease (NCT00339599) | National Cancer Institute (NCI) | 2005-09-20 |
| Intensity Modulated Radiation Therapy for Prostate Cancer (NCT00214422) | National Cancer Institute (NCI) | 2005-09-19 |
| Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate (NCT00265798) | National Cancer Institute (NCI) | 2005-09-14 |
| Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (NCT00217737) | National Cancer Institute (NCI) | 2005-09-06 |
| Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors (NCT00281944) | National Cancer Institute (NCI) | 2005-09-01 |